[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Etac Supply Center Ab\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":52},{"warningLetters":4,"total":51},[5,30],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},680,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-25T04:00:00Z\">08\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsupply-center-usa-710859-08252025\">Supply Center USA\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FOphthalmic Drug Products","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Supply Center USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>30 N Gould St Ste R\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@supplycenterusa.com\"> info@supplycenterusa.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@supplycenterusa.reamaze.com\"> support@supplycenterusa.reamaze.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 25, 2025\u003C\u002Fp>\u003Cp>RE: 710859\u003C\u002Fp>\u003Cp>Dear Supply Center USA:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsupplycenterusa.com in May 2025. The FDA has observed that your website offers “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness &amp; Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>Your unapproved “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness &amp; Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” drug products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\u003Cp>Based on a review of your website, your “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness &amp; Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Fsupplycenterusa.com that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Similasan Allergy Eye Relief (all variations)\u003C\u002Fu>\u003Cbr>On the webpages https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-allergy-eye-relief-eye-drops-20-sterile-single-use-droppers-0-014-fl-oz-0-4-m and https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-allergy-eye-relief-sterile-eye-drops-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“[T]emporarily relieve minor allergy symptoms such as:\u003Cbr>Itching\u003Cbr>Burning\u003Cbr>Excessive watering\u003Cbr>Redness of eye and lids”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Similasan Complete Eye Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-complete-eye-relief-sterileeye-drops-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“When your eyes need multi-symptom relief reach for Similasan Complete Eye Relief sterile eye drops. It stimulates the body's natural ability to temporarily relieve and address eye symptoms like dryness, burning, watering, grittiness, irritation, and redness.”\u003C\u002Fli>\u003Cli>“Uses: According to homeopathic principles, the active ingredients in this medication temporarily relieve minor symptoms such as:\u003Cbr>Redness of eyes and eye lids\u003Cbr>Dry eye\u003Cbr>Reflex watering secondary to dry eye\u003Cbr>Sensation of grittiness\u003Cbr>Sensation of burning”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Similasan Computer Eye Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-computer-eye-relief-sterileeye-drops-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“Uses: According to homeopathic principles, the active ingredients in this product temporarily relieve minor symptoms such as:\u003Cbr>Aching eyes\u003Cbr>Burning\u003Cbr>Redness\u003Cbr>Strained eyes (Computer, TV, reading, driving)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Similasan Pink Eye Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-pink-eye-relief-sterile-eyedrops-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“Use As Often As Needed\u003Cbr>Redness\u003Cbr>Burning\u003Cbr>Watery Discharge\u003Cbr>Sensation of Grittiness”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Similasan Redness &amp; Itchy Eye Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-redness-itchy-eye-relief-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“Uses: According to homeopathic principles, the active ingredients in this product temporarily relieve minor eye symptoms such as:\u003Cbr>itching\u003Cbr>redness of eyes and lids\u003Cbr>excessive watering\u003Cbr>burning\u003Cbr>stinging\u003Cbr>irritation”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Similasan Stye Eye Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-stye-eye-relief-sterile-eyedrops-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“Uses: According to homeopathic principles, the active ingredients in this product temporarily relieve minor symptoms such as:\u003Cbr>Redness\u003Cbr>Burning\u003Cbr>Eyelid Redness\u003Cbr>Tearing”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Similasan Aging Eye Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-aging-eye-relief-0-33-fl-oz-10-ml:\u003C\u002Fp>\u003Cul>\u003Cli>“Uses: According to homeopathic principles, the active ingredients in this medication help temporarily relieve minor symptoms such as:\u003Cbr>Dryness\u003Cbr>Burning\u003Cbr>Irritation\u003Cbr>For protection against further irritation”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Boiron Optique 1 Eye Irritation Relief\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fboiron-optique-1-eye-irritation-relief-30-doses-0-013-fl-oz-each:\u003C\u002Fp>\u003Cul>\u003Cli>“Uses:\u003Cbr>Temporarily relieves minor eye irritation due to fatigue or airborne irritants such as ragweed, other pollens and dust\u003Cbr>Soothes red, dry, itchy, gritty, burning or tired eyes”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness &amp; Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). There are no FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness &amp; Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. You should also refer to the FDA warning letters previously sent to Similasan AG\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and Boiron, Inc.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> about these unapproved ophthalmic drug products.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “710859” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See the Warning Letter issued to Similasan AG on September 11, 2023.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See the Warning Letter issued to Boiron, Inc. on September 11, 2023.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nSupply Center USA\n\n30 N Gould St Ste R\n\nSheridan, WY 82801\n\nUnited States\n\ninfo@supplycenterusa.com\n\nsupport@supplycenterusa.reamaze.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nAugust 25, 2025\nRE: 710859\nDear Supply Center USA:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsupplycenterusa.com in May 2025. The FDA has observed that your website offers “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness & Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nYour unapproved “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness & Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” drug products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\nBased on a review of your website, your “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness & Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Fsupplycenterusa.com that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\nSimilasan Allergy Eye Relief (all variations)\nOn the webpages https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-allergy-eye-relief-eye-drops-20-sterile-single-use-droppers-0-014-fl-oz-0-4-m and https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-allergy-eye-relief-sterile-eye-drops-0-33-fl-oz-10-ml:\n“[T]emporarily relieve minor allergy symptoms such as:\nItching\nBurning\nExcessive watering\nRedness of eye and lids”\nSimilasan Complete Eye Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-complete-eye-relief-sterileeye-drops-0-33-fl-oz-10-ml:\n“When your eyes need multi-symptom relief reach for Similasan Complete Eye Relief sterile eye drops. It stimulates the body's natural ability to temporarily relieve and address eye symptoms like dryness, burning, watering, grittiness, irritation, and redness.”\n“Uses: According to homeopathic principles, the active ingredients in this medication temporarily relieve minor symptoms such as:\nRedness of eyes and eye lids\nDry eye\nReflex watering secondary to dry eye\nSensation of grittiness\nSensation of burning”\nSimilasan Computer Eye Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-computer-eye-relief-sterileeye-drops-0-33-fl-oz-10-ml:\n“Uses: According to homeopathic principles, the active ingredients in this product temporarily relieve minor symptoms such as:\nAching eyes\nBurning\nRedness\nStrained eyes (Computer, TV, reading, driving)”\nSimilasan Pink Eye Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-pink-eye-relief-sterile-eyedrops-0-33-fl-oz-10-ml:\n“Use As Often As Needed\nRedness\nBurning\nWatery Discharge\nSensation of Grittiness”\nSimilasan Redness & Itchy Eye Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-redness-itchy-eye-relief-0-33-fl-oz-10-ml:\n“Uses: According to homeopathic principles, the active ingredients in this product temporarily relieve minor eye symptoms such as:\nitching\nredness of eyes and lids\nexcessive watering\nburning\nstinging\nirritation”\nSimilasan Stye Eye Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-stye-eye-relief-sterile-eyedrops-0-33-fl-oz-10-ml:\n“Uses: According to homeopathic principles, the active ingredients in this product temporarily relieve minor symptoms such as:\nRedness\nBurning\nEyelid Redness\nTearing”\nSimilasan Aging Eye Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fsimilasan-aging-eye-relief-0-33-fl-oz-10-ml:\n“Uses: According to homeopathic principles, the active ingredients in this medication help temporarily relieve minor symptoms such as:\nDryness\nBurning\nIrritation\nFor protection against further irritation”\nBoiron Optique 1 Eye Irritation Relief\nOn the webpage https:\u002F\u002Fsupplycenterusa.com\u002Fproducts\u002Fboiron-optique-1-eye-irritation-relief-30-doses-0-013-fl-oz-each:\n“Uses:\nTemporarily relieves minor eye irritation due to fatigue or airborne irritants such as ragweed, other pollens and dust\nSoothes red, dry, itchy, gritty, burning or tired eyes”\nYour “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness & Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). There are no FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Similasan Allergy Eye Relief” (all variations), “Similasan Complete Eye Relief,” “Similasan Computer Eye Relief,” “Similasan Pink Eye Relief,” “Similasan Redness & Itchy Eye Relief,” “Similasan Stye Eye Relief,” “Similasan Aging Eye Relief,” and “Boiron Optique 1 Eye Irritation Relief” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. You should also refer to the FDA warning letters previously sent to Similasan AG1 and Boiron, Inc.2 about these unapproved ophthalmic drug products.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “710859” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n____________________\n1 See the Warning Letter issued to Similasan AG on September 11, 2023.\n2 See the Warning Letter issued to Boiron, Inc. on September 11, 2023.","Supply Center USA","supply-center-usa-710859-08252025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsupply-center-usa-710859-08252025","2026-10-26T08:10:08.037553+00:00","Warning Letter","Issued","2025-09-02","710859","Drugs","2026-08-19T16:27:30.352+00:00","Via Email","2025-08-25",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":45,"medical_device_id":19,"response_letter_date":19},1974,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2023-07-27T13:50:00Z\">07\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-27T04:00:00Z\">07\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fec-supply-inc-662038-07272023\">EC Supply, Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne W. Chang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CFO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>EC Supply, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13453 Brooks Drive, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baldwin Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wayne@ECsupplyinc.com\"> wayne@ECsupplyinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chang:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that EC Supply, Inc. distributes Electronic Nicotine Delivery Systems (ENDS) products for commercial distribution in the United States, and that the ENDS products are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you sell and\u002For distribute to customers in the United States ENDS products that lack a marketing authorization order, including: EB Design BC5000 Disposable Pod Device Blue Razz Ice 50 mg\u002Fml and Pastel Cartel Esco Bars Mesh Watermelon Ice 5% 50mg\u002Fml 2500 puffs.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300883, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nWayne W. Chang\n\nRecipient Title\n\nCFO\n\nEC Supply, Inc.\n\n13453 Brooks Drive, Suite A\n\nBaldwin Park, CA 91706\n\nUnited States\n\nwayne@ECsupplyinc.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Chang:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that EC Supply, Inc. distributes Electronic Nicotine Delivery Systems (ENDS) products for commercial distribution in the United States, and that the ENDS products are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you sell and\u002For distribute to customers in the United States ENDS products that lack a marketing authorization order, including: EB Design BC5000 Disposable Pod Device Blue Razz Ice 50 mg\u002Fml and Pastel Cartel Esco Bars Mesh Watermelon Ice 5% 50mg\u002Fml 2500 puffs.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300883, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","EC Supply, Inc.","ec-supply-inc-662038-07272023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fec-supply-inc-662038-07272023","2026-10-26T08:08:30.499826+00:00","2023-07-27","662038","Tobacco","Wayne W. Chang","2026-08-20T00:50:54.502+00:00","VIA UPS and Electronic Mail",2,{"510k":53,"classification":54,"enforcement":55,"event":56,"event_backfill":57,"pma":58,"warning_letter":59},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]